Citius Oncology Closes $18 Million Financing to Support LYMPHIR Launch
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 21 hour ago0mins
- Successful Financing: Citius Oncology closed a registered direct offering with a single healthcare investor, selling 1,284,404 shares at $1.09 each, raising approximately $18 million to enhance liquidity for new product launches.
- Private Placement Completion: The company also completed a private placement of 15,229,358 shares at the same price, with accompanying warrants, which will strengthen the capital structure and support future commercial expansion.
- Market Potential: The initial market for LYMPHIR is estimated to exceed $400 million and remains underserved by existing therapies, with proceeds from the financing aimed at driving commercialization, significantly enhancing the company's competitive position in oncology.
- Strategic Partnership: H.C. Wainwright & Co. acted as the exclusive placement agent, indicating professional support in capital markets, which will help attract more investor interest in Citius Oncology's growth potential.
CTOR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CTOR
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.130
Low
6.00
Averages
6.00
High
6.00
Current: 1.130
Low
6.00
Averages
6.00
High
6.00
Maxim
Michael Okunewitch
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Michael Okunewitch
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim analyst Michael Okunewitch upgraded Citius Oncology to Buy from Hold with a $6 price target.
Maxim
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim upgraded Citius Oncology to Buy from Hold with a $6 price target. The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a "key event" for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could "ramp quickly" in 2026, the firm added.
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Oncology to Hold from Buy.
See All Ratings
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of LYMPHIR's FDA approval for CTCL treatment?
How does the partnership with Cardinal Health support LYMPHIR's U.S. distribution?
How might LYMPHIR's market entry impact Citius Oncology's revenue growth in 2024?
What are the potential outcomes of Citius Oncology's partnership with Er-Kim?